Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell.
Of Interest
MyMelanoma study selected to join NHS DigiTrials initiative
Three projects – including the Oxford-led MyMelanoma study – have been selected to join an NHS initiative, which aims to sign up tens of thousands of volunteers over the next two years to help improve the diagnosis and treatment of cancer patients.
What Is Known About Psychosocial Wellbeing in Patients With Melanoma In Situ?
A significant gap in research on psychosocial wellbeing among patients newly diagnosed with melanoma in situ (MIS) exists, according to the results of a systematic review published in Melanoma Research.
Lymphoid Aggregates as Positive Prognostic in Overall Survival for Melanoma
Because the prevalence and impact of immature precursor lymphoid structures known as lymphoid aggregates (LAs) remain unresolved in relation to metastatic cutaneous melanoma disease progression, researchers examined the characteristics and prognostic ability of LAs and tertiary lymphoid structures (TLSs) in histologic samples from patients with melanoma.